Acurx Pharmaceuticals, Inc. (ACXP)
1.43
+0.01
(+0.70%)
USD |
NASDAQ |
Sep 08, 16:00
1.435
0.00 (0.00%)
Pre-Market: 20:00
Acurx Pharmaceuticals Net Income (Quarterly) : -2.254M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.254M |
| March 31, 2026 | -1.681M |
| December 31, 2025 | -1.578M |
| September 30, 2025 | -1.993M |
| June 30, 2025 | -2.246M |
| March 31, 2025 | -2.149M |
| December 31, 2024 | -2.782M |
| September 30, 2024 | -2.822M |
| June 30, 2024 | -4.122M |
| March 31, 2024 | -4.378M |
| December 31, 2023 | -5.115M |
| September 30, 2023 | -3.115M |
| Date | Value |
|---|---|
| June 30, 2023 | -3.445M |
| March 31, 2023 | -2.903M |
| December 31, 2022 | -3.260M |
| September 30, 2022 | -3.542M |
| June 30, 2022 | -2.620M |
| March 31, 2022 | -2.670M |
| December 31, 2021 | -2.627M |
| September 30, 2021 | -4.642M |
| June 30, 2021 | -4.004M |
| March 31, 2021 | -1.474M |
| June 30, 2020 | -0.9134M |
| March 31, 2020 | -1.279M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.254M |
| EPS Diluted (Quarterly) | -0.5292 |
| Enterprise Value | -3.959M |
| Earnings Yield | -213.0% |
| Normalized Earnings Yield | -212.96 |